Granules India Limited — Important, 27-02-2025: General Updates

Granules India has addressed the recent Warning Letter issued by the US FDA regarding its Gagillapur facility. Despite this development, the facility continues to manufacture and distribute existing products without interruption. The Warning Letter is expected to temporarily affect the FDA's review of pending product submissions until the issues are resolved.

To strengthen compliance, Granules has implemented a comprehensive remediation plan, including corrective and preventive actions, oversight by independent consulting firms, and ongoing product testing. Regular updates have been provided to the FDA, demonstrating significant progress on corrective actions against the four key areas highlighted in the FDA's observations.

Granules maintains a robust and diversified growth trajectory, driven by new product launches in the US, expansion in large-volume products, capacity additions, and advancements in its oncology pipeline. This strategy emphasizes sustained performance and mitigates reliance on resolutions from the Gagillapur facility. Investors should watch closely as the company works through these regulatory challenges while pursuing broader growth opportunities.